Evoke Pharma Past Earnings Performance
Past criteria checks 0/6
Evoke Pharma has been growing earnings at an average annual rate of 0.9%, while the Pharmaceuticals industry saw earnings declining at 0.8% annually. Revenues have been growing at an average rate of 71.5% per year.
Key information
0.9%
Earnings growth rate
17.2%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 71.5% |
Return on equity | n/a |
Net Margin | -150.4% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely
Jan 22Evoke to get US patent for nasal spray Gimoti
Sep 20Evoke Pharma Q2 GAAP loss per share narrows, revenue up
Aug 10Evoke Pharma gets Canadian patent linked to Gimoti nasal spray
Jul 06Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Oct 22Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Jul 06Evoke Pharma announces positive findings from second GIMOTI market research study
Jun 15Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book
Jun 08Evoke Pharma issued new U.S. patent covering methods of use for Gimoti
Jun 02Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit
Mar 14Evoke Pharma shares surge on positive findings from Gimoti market research study
Jan 13Evoke Pharma EPS beats by $0.02
Nov 10Revenue & Expenses BreakdownBeta
How Evoke Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 5 | -8 | 12 | 0 |
30 Sep 23 | 4 | -8 | 11 | 0 |
30 Jun 23 | 4 | -8 | 11 | 0 |
31 Mar 23 | 3 | -8 | 10 | 0 |
31 Dec 22 | 3 | -8 | 10 | 0 |
30 Sep 22 | 2 | -8 | 9 | 0 |
30 Jun 22 | 2 | -8 | 9 | 0 |
31 Mar 22 | 2 | -8 | 9 | 0 |
31 Dec 21 | 2 | -9 | 9 | 1 |
30 Sep 21 | 1 | -9 | 9 | 1 |
30 Jun 21 | 0 | -9 | 8 | 1 |
31 Mar 21 | 0 | -14 | 7 | 6 |
31 Dec 20 | 0 | -13 | 6 | 7 |
30 Sep 20 | 0 | -12 | 5 | 7 |
30 Jun 20 | 0 | -12 | 4 | 8 |
31 Mar 20 | 0 | -7 | 4 | 3 |
31 Dec 19 | 0 | -7 | 4 | 3 |
30 Sep 19 | 0 | -7 | 4 | 3 |
30 Jun 19 | 0 | -7 | 4 | 3 |
31 Mar 19 | 0 | -8 | 4 | 3 |
31 Dec 18 | 0 | -8 | 4 | 4 |
30 Sep 18 | 0 | -6 | 4 | 5 |
30 Jun 18 | 0 | -10 | 4 | 7 |
31 Mar 18 | 0 | -9 | 4 | 8 |
31 Dec 17 | 0 | -12 | 4 | 7 |
30 Sep 17 | 0 | -13 | 4 | 7 |
30 Jun 17 | 0 | -11 | 4 | 6 |
31 Mar 17 | 0 | -13 | 4 | 6 |
31 Dec 16 | 0 | -11 | 4 | 7 |
30 Sep 16 | 0 | -12 | 4 | 7 |
30 Jun 16 | 0 | -12 | 4 | 8 |
31 Mar 16 | 0 | -12 | 4 | 8 |
31 Dec 15 | 0 | -12 | 4 | 8 |
30 Sep 15 | 0 | -12 | 4 | 9 |
30 Jun 15 | 0 | -14 | 3 | 10 |
31 Mar 15 | 0 | -14 | 3 | 11 |
31 Dec 14 | 0 | -13 | 3 | 10 |
30 Sep 14 | 0 | -12 | 3 | 8 |
30 Jun 14 | 0 | -9 | 3 | 5 |
31 Mar 14 | 0 | -5 | 2 | 3 |
31 Dec 13 | 0 | -3 | 2 | 1 |
30 Sep 13 | 0 | -2 | 1 | 1 |
Quality Earnings: EVOK is currently unprofitable.
Growing Profit Margin: EVOK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EVOK is unprofitable, but has reduced losses over the past 5 years at a rate of 0.9% per year.
Accelerating Growth: Unable to compare EVOK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EVOK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.7%).
Return on Equity
High ROE: EVOK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.